AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23756581
Drug: TrentinGrana cheese
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TrentinGrana cheese (lysozyme-free, 30 g)
Trial: 2213803
Drug: Automated External
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated External Defibrillator (AED) as an adjunct to basic life support
Trial: 619237
Drug: Leg injection
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leg injection
Trial: 619237
Drug: Abdominal injection
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal injection
Trial: 28858080
Drug: Acarbose +
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose + insulin
Trial: 28858080
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + insulin
Trial: 10393618
Drug: L-amino acid-based
RxNorm normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-amino acid-based elemental formula (AAF)
Trial: 1909274
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of Intron‐A trice weekly for 6 months (Group A)
Trial: 1909274
Drug: Dose titration
RxNorm normalized name: Rebif Rebidose Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration according to ALT-AST values (Group B)
Trial: 1909274
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: no treatment for 6 months (Group D)
Trial: 6636797
Drug: Euphyllin retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphyllin retard 350 mg
Trial: 6636797
Drug: Mundiphyllin retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mundiphyllin retard 225 mg
Trial: 6636797
Drug: Intravenous Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Theophylline (10 mg/kg body weight over 24 hours)
Trial: 31287010
Drug: Mindful-compassion art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful-compassion art therapy (MCAT)
Trial: 25412293
Drug: Injected placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected placebo (OxyRBX) - subcutaneous saline injections daily during the placebo phase
Trial: 18303488
Drug: Bexarotene (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexarotene (75 mg/d)
Trial: 15271195
Drug: Ciclopirox 1%
RxNorm normalized name: Ciclopirox 1% Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox 1% shampoo applied once weekly
Trial: 15271195
Drug: Ciclopirox 1%
RxNorm normalized name: Ciclopirox 1% Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox 1% shampoo applied twice weekly
Trial: 15271195
Drug: Ciclopirox 1%
RxNorm normalized name: Ciclopirox 1% Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox 1% shampoo applied three times weekly
Trial: 7995184
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei strain GG 10(10) colony-forming units twice daily for five days
Trial: 3135047
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection of adrenaline
Trial: 29871798
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz rTMS administered over the right parietal lobe for 10 days
Trial: 27018305
Drug: Assisted Cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assisted Cycling Therapy (ACT)
Trial: 16041840
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (100-300 mg per day for 4 weeks)
Trial: 7818104
Drug: Ketorolac (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (1 mg/kg)
Trial: 7818104
Drug: Acetaminophen (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (35 mg/kg)
Trial: 6345178
Drug: Prazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (1 mg twice daily)
Trial: 6345178
Drug: Prazosin (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (highest tolerated dose 2-8 mg daily)
Trial: 31200437
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein (HP, n = 22) - 1.2 g protein·kg‐1·d‐1
Trial: 31200437
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein (NP, n = 25) - 0.8 g protein·kg‐1·d‐1
Trial: 30045757
Drug: Medication monitor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication monitor-based treatment strategy
Trial: 24461395
Drug: On-demand ibuprofen
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand ibuprofen (400 mg single dose plus rescue medication)
Trial: 24461395
Drug: Regular ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular ibuprofen (400 mg every 6 hours for at least 24 hours)
Trial: 22033897
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection of hyaluronic acid (HA) and contrast dye
Trial: 22033897
Drug: Blind injection
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind injection of hyaluronic acid (HA) and contrast dye
Trial: 19084273
Drug: Travatan Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travatan Dosing Aid (DA; Alcon, Fort Worth, TX)
Trial: 17932361
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg of folic acid plus 5 mg of riboflavin
Trial: 15754276
Drug: Intravenous ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate (250 mg/wk, subsequently increased to 500 mg/wk)
Trial: 15754276
Drug: Intravenous ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate (500 mg/wk)
Trial: 15754276
Drug: Intravenous ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate (250 mg/wk and 500 mg/wk)
Trial: 15754276
Drug: Intravenous ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate (during supplementation)
Trial: 12401606
Drug: Hyperbaric lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric lidocaine 25 mg with fentanyl 20 microg (n = 37)
Trial: 12401606
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 4 mg with fentanyl 20 microg (n = 35)
Trial: 10190377
Drug: Ciprofloxacin 100
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 100 mg twice daily for 3 days
Trial: 10190377
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg twice daily for 3 days
Trial: 10190377
Drug: Trimethoprim/sulfamethoxazole 160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole 160/800 mg twice daily for 3 days
Trial: 7549296
Drug: Hypo-osmolar ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypo-osmolar ORS containing L-alanine and glucose (osmolality 255 mosmol/l)
Trial: 7549296
Drug: WHO-ORS (osmolality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO-ORS (osmolality 311 mosmol/l)
Trial: 7549296
Drug: i.v. polyelectrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. polyelectrolyte solutions (osmolality 293 mosmol/l)
Trial: 18294410
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol 100 mg
Trial: 15777304
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine plus ketorolac (K group)
Trial: 15777304
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine (M group)
Trial: 12007762
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg or 30 mg)
Trial: 10715786
Drug: EVL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVL treatment
Trial: 7767523
Drug: NPPV (noninvasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPPV (noninvasive positive pressure ventilation) administered by nasal mask connected to a BiPAP device
Trial: 7767523
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (control)
Trial: 31755959
Drug: Unconventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconventional treatment (more than two lines)
Trial: 17259059
Drug: Greater intercourse
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater intercourse frequency and pill use
Trial: 15115249
Drug: Standard clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clamp (insulin‐infusion rate 30 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Trial: 15115249
Drug: Hyperinsulinaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Trial: 15115249
Drug: Hyperinsulinaemic, hyperglycaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinaemic, hyperglycaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 12.0 mmol/L)
Trial: 11257150
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and pulse cyclophosphamide (0.7 g/m2 at diagnosis) followed by either pulse or oral cyclophosphamide (2 mg/kg/day)
Trial: 11257150
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and cyclophosphamide treatment
Trial: 9481149
Drug: Computerized version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computerized version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Trial: 9481149
Drug: Paper and
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper and pencil version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Trial: 25002833
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (nutrition support commenced via gastrostomy when clinically indicated during treatment)
Trial: 22897671
Drug: Synthetic gel
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic gel model
Trial: 20485955
Drug: Hypobaric 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric 0.15% bupivacaine (3 mL, 4.5 mg)
Trial: 20485955
Drug: Hypobaric 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric 0.6% lidocaine (3 mL, 18 mg)
Trial: 12871461
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin E at 900 IU day(-1), vitamin C at 2000 mg day(-1)) for 6 weeks
Trial: 12871461
Drug: Anti-beta(2) glycoprotein
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-beta(2) glycoprotein 1 (beta(2)GP(1)) antibodies
Trial: 8571024
Drug: Low-dose hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose hormonal contraceptive (gestodene 75 mcg + ethinylestradiol 30 mcg)
Trial: 25455039
Drug: Symbiotic gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin)
Trial: 16534049
Drug: Single-dose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (1 g) oral azithromycin
Trial: 16534049
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin for household members (20 mg/kg up to 1 g) plus the patient
Trial: 22159169
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline (twice per day for 6 weeks)
Trial: 10673249
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg/d for 1 month
Trial: 1790067
Drug: Josamycin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin (750 mg/12 h/orally)
Trial: 1790067
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (500 mg/8 h)
Trial: 28719717
Drug: Sildenafil (Viagra)
RxNorm normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil (Viagra) at 50 mg twice a week for 3 weeks
Trial: 28719717
Drug: Tadalafil (Cialis)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil (Cialis) at 20 mg twice a week for 3 weeks
Trial: 28719717
Drug: Vardenafil (Levitra)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vardenafil (Levitra) at 20 mg twice a week for 3 weeks
Trial: 24558764
Drug: Land-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based exercise therapy
Trial: 19244540
Drug: Sulpiride (D(2)
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (D(2) antagonist)
Trial: 19244540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulpiride and L-dopa
Trial: 15637825
Drug: Self‐administered survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered survey
Trial: 30192928
Drug: Low-dose scopolamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose scopolamine (0.2 mg IV)
Trial: 27492015
Drug: Irinotecan 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 110 mg/m2 on day 1 and 100 mg/m2 on day 8 plus cisplatin 80 mg/m2 on day 8 every 3 weeks (IC arm)
Trial: 27492015
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus cisplatin 80 mg/m2 on day 1 every 3 weeks (PC arm)
Trial: 25475357
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg in divided doses)
Trial: 14662281
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg/2.5 mg respectively)
Trial: 8957972
Drug: 0.25% caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% caudal bupivacaine 0.5 ml kg‐1 and diamorphine 30 micrograms kg‐1
Trial: 8957972
Drug: 0.25% caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% caudal bupivacaine 0.5 ml kg‐1 alone
Trial: 3911482
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) initial dose 240 U (anti F Xa)/kg/12 h in study I; 120 U (anti F Xa)/kg/12 h in study II
Trial: 3911482
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) initial dose 240 U/kg/12 h in both studies
Trial: 16873380
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 40 mg and 80 mg doses
Trial: 16271643
Drug: Metoprolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (up to 15 mg intravenous then 200 mg oral daily; n=22,929)
Trial: 2404480
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg/d for 14 days
Trial: 334227
Drug: Nomifensine (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (50-200 mg daily)
Trial: 334227
Drug: Amitriptyline (50-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50-225 mg daily)
Trial: 30770291
Drug: Standard radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiotherapy - 66 Gy in 33 daily 2 Gy fractions or 50 Gy in 20 daily 2.5 Gy fractions, depending on institutional preference.
Trial: 24036915
Drug: Visual stimuli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual stimuli designed to elicit variable V1 response spread, details on dosage and duration not available.
Trial: 18830816
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Tamoxifen
Trial: 18323331
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg, twice daily (BID)
Trial: 3420976
Drug: FBKC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBKC vaccine
Trial: 3420976
Drug: PCEC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEC vaccine
Trial: 3420976
Drug: PVRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV vaccine
Trial: 24341101
Drug: Shuganyiyang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuganyiyang Capsule combined with tamsulosin hydrochloride sustained release tablets and prostat tablets
Trial: 16080273
Drug: rizatriptan capsule
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rizatriptan capsule preparation (test)
Trial: 16080273
Drug: rizatriptan tablet
RxNorm normalized name: rizatriptan Oral Tablet
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rizatriptan tablet (reference)
Trial: 8949806
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 with thiopentone 5 mg kg‐1
Trial: 8949806
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 with propofol 2.5 mg kg‐1
Trial: 8949806
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 with propofol 2.5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Trial: 8949806
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 with thiopentone 5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Trial: 1921398
Drug: Combined application
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil
Trial: 1921398
Drug: IHA chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHA chemotherapy with the same chemotherapeutic regimen
Trial: 17514537
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1 (T1): 2,092 kJ/day (500 kcal/day) peanuts for 8 weeks
Trial: 17514537
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (T2): 2,092 kJ/day (500 kcal/day) peanuts for 3 weeks
Trial: 17514537
Drug: Treatment 3
RxNorm normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3 (T3): Substitution of 2,092 kJ/day fat with energy from peanuts
Trial: 14605042
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 50 mg IM injection on days 1, 15, 29, and 43
Trial: 14605042
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 50 mg IM injection
Trial: 14605042
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of arachis oil)
Trial: 11040170
Drug: Topical amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical amethocaine gel (4% w/w, 1.5 g applied under occlusion for one hour)